Table 3.
Overview of the three studies investigating MRI volumetry of neoadjuvant chemotherapy (NACT) response in locally advanced rectal cancer as a predictor of tumour regression grade (TRG) after NACT followed by chemoradiotherapy
| Author | Nougaret et al16 | Aiba et al17 | Present study |
|---|---|---|---|
| Patient characteristics | |||
| Number of patients | 16 | 40 | 69 |
| T stage | Locally advanced | T3 (32%) + T4 (67%) | T2 (3%) + T3 (61%) + T4 (36%) |
| Tumour volume (cm3)a | 132 ± 166 | 29.3 (3.5–262.3) | 16.1 (1.1–293.4) |
| Method | |||
| Good responder | TRGs 3–4 (Dworak) | TRGs 3–4 (Dworak et al24) | TRGs 1–2 (Bouzourene et al23) |
| MRI | T2W ≤1 mm3 | T2W ≤1 mm3 | T2W ≤1 mm3 |
| Reading | Single radiologist | Experienced radiologist and surgeon | Experienced radiologist |
| Treatment | |||
| NACT | FOLFIRINOX | XELOX, FOLFOX | Nordic FLOX |
| Time point (weeks) | 8 | 4–8 | 4 |
| Results | |||
| ∆V (%)a | −68 (±27) | −60 (+23.5 to −93.9) | −65 (+26.2 to −96.4) |
| Accuracy—receiver operating characteristics analyses (%) | 68 | 70 | 78 |
| Sensitivity for 100% specificity (%) | 86 | 55–60 | 38 |
| Cut-off ∆V (%) for 100% specificity | 70 | NA | 78 |
FLOX, fluorouracil + oxaliplatin; FOLFIRINOX, folinic acid + fluorouracil + irinotecan + oxaliplatin; FOLFOX, folinic acid + fluorouracil + oxaliplatin; NA, not applicable; T2W, T2 weighted; XELOX, capecitabine + oxaliplatin.
a
Mean ± standard deviation or median (range).